In NSCLC, the observed drug-induced effects upon a number of multiple biomarkers including Ki-67, BrdU uptake to measure ongoing proliferative activity as well as of cleaved caspase-3 as key protein of the terminal phase in the apoptotic pathway are in good agreement with existing data from both experimental [16,24] and clinical studies [25,26]. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.